AWA do zlecenia 045/2012 - AOTM

Copaxone (octan glatirameru) AOTM-OT-4351-1/2012
I linia leczenia chorych na stwardnienie rozsiane w postaci rzutowo-remisyjnej
37. HAS 2010
38.
HAS 2011
39. Int. cons.2002
40. IPMSSG 2007
41. IPMSSG 2010
42. IRF 2010
43. Johnson 2000
44. Johnson 2003
45. Johnston 2012
46. Jongen 2010
47.
48.
49. Kornek 2003
50. Krupp 2007
51. La Mantia 2010
52. Loma 2011
53. Lublin 1996
54.
55. Metz 2004
56. Mikol 2008
http://www has-sante fr/portail/upload/docs/application/pdf/ct031354.pdf
Haute Autorité de Santé, Examen du dossier de la spécialité inscrite pour une durée de 5
ans à compter du 27/08/2009
http://www has-sante fr/portail/upload/docs/application/pdf/2010-07/copaxone - ct-
5615.pdf
Sclérose en plaques Interférons β et acétate de glatiramère Réévaluation
http://www has-sante fr/portail/upload/docs/application/pdf/2010-
08/annexe reevaluation inf ag - sep 2010-08-04 11-12-15 399.pdf
Haute Autorité de Santé, COPAXONE 20 mg/ml, solution injectable, seringue préremplie,
B/28 CIP : 363 840-1
http://www has-sante fr/portail/upload/docs/application/pdf/2011-05/copaxone - ct-
9471.pdf
Freedman et al, International consensus statement on the use of disease-modifying agents
in multiple sclerosis. Mult Scler February 2002; 8, 1, 19-23
http://msj.sagepub.com/content/8/1/19.abstract
International Pediatric MS Study Group, Treatment of pediatric multiple sclerosis and
variants
http://www neurology.org/content/68/16 suppl 2/S54
Consensus Statement: Evaluation of new and existing therapeutics for pediatric MS:
International Pediatric MS Study Group
Institut for Rationel Farmakoterapi Sygdomsmodificerende behandling af multipel
sklerose, Sygdomsmodificerende behandling af multipel sklerose
http://www.irf.dk/dk/publikationer/rationel farmakoterapi/maanedsblad/2010/sygdomsmo
dificerende_behandling_af_multipel_sklerose htm
Johnson KP, Brooks BR, Ford CC et al. Sustained clinical benefits of glatiramer acetate in
relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis
Study Group. Mult Scler. 2000 Aug;6(4), 255-266.
Johnson KP, Brooks BR, Ford CC et al. Glatiramer acetate (Copaxone): comparison of
continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult
Scler. 2003 Dec;9(6), 585-591.
Johnston J, So T-Y. First-line disease-modifying therapies in paediatric multiple sclerosis.
Drugs 2012; 72(9):1195-1211.
Jongen PJ, Hengstman G, Hupperts R et al. Drug adherence and multidisciplinary care in
patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred,
nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study). BMC
Neurol. 2011 Mar 30;11:40.
Kornek B, Bernert G, Balassy C, Geldner J et al Glatiramer acetate treatment in patients
with childhood and juvenile onset multiple sclerosis. Neuropediatrics 2003 Jun;34(3):120-
6.
Krupp LB, Banwell B, Tenembaum S. International Pediatric MS Study Group.
Consensus definitions proposed for pediatric multiple sclerosis and related disorders.
Neurology. 2007 Apr 17;68(16 Suppl 2):S7-12.
La Mantia L, Munari L M, Lovati R. Glatiramer acetate for multiple sclerosis. Cochrane
Database Syst Rev. 2010 May 12;(5):CD004678
Loma I., Heyman R. Multiple sclerosis:pathogenesis and treatment. Current
Neuropharmacology 2011; 9:409-416.
Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an
international survey. Neurology 1996; 46: 907–911.
Metz LM, Patten S, Archibald CJ et al. The effect of immunomodulatory treatment on
multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry. 2004 Jul;75(7), 1045-1047.
Mikol DD, Barkhof F, Chang P et al. REGARD study group. Comparison of subcutaneous
interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the
Analiza weryfikacyjna Agencji Oceny Technologii Medycznych 110/113